Supernus Pharmaceuticals earnings were -$38.6M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest SUPN earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$4.1M, down 90.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SUPN reported annual earnings of -$38.6M, with -152.2% growth.
Supernus Pharmaceuticals Earnings Reports & History FAQ
What were Supernus Pharmaceuticals's earnings last quarter?
On SUPN's earnings call on Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q4 2025 earnings per share (EPS) of -$0.07, up 125% year over year. Total SUPN earnings for the quarter were -$4.11 million. In the same quarter last year, Supernus Pharmaceuticals's earnings per share (EPS) was $0.28.
Is Supernus Pharmaceuticals profitable or losing money?
As of the last Supernus Pharmaceuticals earnings report, Supernus Pharmaceuticals is currently losing money. Supernus Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$38.55 million, a 152.19% decrease year over year.
What was SUPN's earnings growth in the past year?
As of Supernus Pharmaceuticals's earnings date in Invalid Date, Supernus Pharmaceuticals's earnings has grown year over year. SUPN earnings in the past year totalled -$38.55 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.